Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
90Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $294.28M | $367.02M | $20.40 |
| 2024 | $179.28M | $17.48M | $0.99 |
| 2023 | $116.88M | $-25.09M | $-1.44 |
| 2022 | $120.24M | $-58.57M | $-3.40 |
| 2021 | $149.24M | $-17.91M | $-1.10 |
Social Signal Score
Earnings
Tue, Nov 3(in 3 months)
Consensus estimate $0.89 per share
Typical surprise +66.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.88 vs $0.09beat
- Tue, May 5$0.44 vs $0.74miss
- Tue, Mar 3$1.14 vs $1.33miss
- Tue, Nov 4$1.46 vs $0.93beat
- Tue, Aug 5$3.28 vs $1.97beat
- Tue, May 6$0.63 vs $0.14beat
Estimates and results for RIGL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $29.98
- Implied price
- $539.67
- Return from $42.58
- 66.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $268.31 — today's price is already 84.1% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 39.0% | 45.4% | 50.8% | 55.5% | 59.7% |
| 3.0% | 46.1% | 52.8% | 58.5% | 63.5% | 67.9% |
| 8.0% | 53.2% | 60.2% | 66.2% | 71.4% | 76.0% |
| 13.0% | 60.3% | 67.6% | 73.9% | 79.3% | 84.2% |
| 18.0% | 67.4% | 75.1% | 81.6% | 87.3% | 92.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsprnewswire.com·2d ago·Negative
…atment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANUTM (vepdegestrant) is now available by prescription in the United States for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 …
View source ↗